SG11201907276TA - Compositions of gallium (iii) complexes for oral administration - Google Patents

Compositions of gallium (iii) complexes for oral administration

Info

Publication number
SG11201907276TA
SG11201907276TA SG11201907276TA SG11201907276TA SG11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA
Authority
SG
Singapore
Prior art keywords
international
gaq3
lexi
vancouver
pharma
Prior art date
Application number
SG11201907276TA
Inventor
Rickey Rhinebarger
Gina Stetsko
Original Assignee
Altum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altum Pharmaceuticals Inc filed Critical Altum Pharmaceuticals Inc
Publication of SG11201907276TA publication Critical patent/SG11201907276TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIP0 1 PCT oimioio VIII °nolo VIII Ill Em mil Inv X11 oimiE (10) International Publication Number WO 2018/146551 A2 W O 20 18/ 14655 1 A2 (51) International Patent Classification: A61K 31/47 (2006.01) (21) International Application Number: PCT/IB2018/000213 (22) International Filing Date: 09 February 2018 (09.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/457,712 10 February 2017 (10.02.2017) US (71) Applicant: LEXI PHARMA INC. [CA/CA]; 1055 West Georgia Street, Suite 2100, P. 0. Box 11110, Royal Centre, Vancouver, BC V6E 3P3 (CA). (72) Inventors: RHINEBARGER, Rickey, Roy; c/o Lexi Pharma Inc., 1055 West Georgia Street, Suite 2100, P.O. Box 11110, Royal Centre, Vancouver, BC V6E 3P3 (CA). STETSKO, Gina, G.; c/o Lexi Pharma Inc., 1055 West Georgia Street, Suite 2100, P.O. Box 11110, Royal Centre, Vancouver, BC V6E 3P3 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) = (54) Title: COMPOSITIONS OF GALLIUM (III) COMPLEXES FOR ORAL ADMINISTRATION (57) : The present invention relates to dosage forms of galli- um complexes suitable for oral very and methods of preparation there- of Such dosage forms are useful for the treatment of diseases, includ- ing, but not limited to, cancer. A . Lua. ow: 1 B — amorphous GaQ3:liedragit 1,1011/1:1 wetted C =amomhous GaQ3:1\"VP-K12 I) = amorphous 003:11PVICP, 1155/ 1 - .1 oryrtal line GaQ3 F1GURF, 1
SG11201907276TA 2017-02-10 2018-02-09 Compositions of gallium (iii) complexes for oral administration SG11201907276TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762457712P 2017-02-10 2017-02-10
PCT/IB2018/000213 WO2018146551A2 (en) 2017-02-10 2018-02-09 Compositions of gallium (iii) complexes for oral administration

Publications (1)

Publication Number Publication Date
SG11201907276TA true SG11201907276TA (en) 2019-09-27

Family

ID=63106002

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907276TA SG11201907276TA (en) 2017-02-10 2018-02-09 Compositions of gallium (iii) complexes for oral administration

Country Status (15)

Country Link
US (2) US10548849B2 (en)
EP (1) EP3582778B1 (en)
JP (1) JP2020513030A (en)
KR (1) KR20190121784A (en)
CN (1) CN110381945A (en)
AU (1) AU2018218326A1 (en)
BR (1) BR112019016400A2 (en)
CA (1) CA3051545A1 (en)
IL (1) IL268379A (en)
MX (1) MX2019009510A (en)
MY (1) MY194485A (en)
PH (1) PH12019501868A1 (en)
RU (1) RU2019128191A (en)
SG (1) SG11201907276TA (en)
WO (1) WO2018146551A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098306C (en) * 2018-05-14 2024-04-16 Capsugel Belgium Nv Solid dosage forms with high active agent loading

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004951A (en) * 1989-11-22 1999-12-21 Bernstein; Lawrence Richard Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual
CN1917889A (en) * 2003-12-17 2007-02-21 泰坦医药品公司 Use of gallium to treat inflammatory arthritis
US20070098815A1 (en) 2005-10-27 2007-05-03 Bernstein Lawrence R Orally Administrable Gallium Compositions and Methods of Use
ZA200803283B (en) * 2005-11-04 2009-11-25 Genta Inc Pharmaceutical gallium compositions and methods
PE20081506A1 (en) * 2006-12-12 2008-12-09 Infinity Discovery Inc ANSAMYCIN FORMULATIONS
KR101783676B1 (en) 2010-02-12 2017-10-10 니키 파머 액퀴지션 코포레이션 2 Method for treating hematological cancers
EP2560648A4 (en) 2010-04-23 2013-10-02 Niiki Pharma Inc Method for treating pancreatic cancer
US20140127271A1 (en) * 2012-04-11 2014-05-08 Intezyne Technologies, Inc. Block copolymers for stable micelles
TWI615157B (en) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 Solid dispersion comprising amorphous cilostazol
CN105530918A (en) * 2013-09-25 2016-04-27 陶氏环球技术有限责任公司 Composition comprising an organic liquid diluent and a specific hydroxyalkyl methylcellulose

Also Published As

Publication number Publication date
PH12019501868A1 (en) 2020-07-06
EP3582778A4 (en) 2020-12-23
US10933021B2 (en) 2021-03-02
MY194485A (en) 2022-11-30
EP3582778B1 (en) 2022-10-05
CN110381945A (en) 2019-10-25
WO2018146551A2 (en) 2018-08-16
KR20190121784A (en) 2019-10-28
AU2018218326A1 (en) 2019-08-22
WO2018146551A3 (en) 2018-10-04
EP3582778A2 (en) 2019-12-25
CA3051545A1 (en) 2018-08-16
US20200038334A1 (en) 2020-02-06
BR112019016400A2 (en) 2020-04-07
JP2020513030A (en) 2020-04-30
WO2018146551A4 (en) 2018-11-22
IL268379A (en) 2019-09-26
RU2019128191A (en) 2021-03-10
US20180228734A1 (en) 2018-08-16
US10548849B2 (en) 2020-02-04
RU2019128191A3 (en) 2021-05-31
MX2019009510A (en) 2019-11-25

Similar Documents

Publication Publication Date Title
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201907023UA (en) Method of reducing neutropenia
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201808314QA (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
SG11201908171TA (en) Compounds and compositions for treating hematological disorders
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201808686VA (en) Synthesis of indazoles
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201811559WA (en) Cancer treatment combinations
SG11201805001UA (en) Method of treating influenza a
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201806140SA (en) Stable liquid gonadotropin formulation